Inactive Instrument

Other languages Eisai Co., Ltd. OTC Markets

Equities

ESALY

US2825793092

Other languages

Unlock all the news: Be the first to know and act before the market!

Eli Lilly Alzheimer's drug approved by US FDA	07-02
Eisai Repurchases 4.8 Billion Yen Worth of Shares in June	07-02
Japan's Eisai developing dementia drug for US market, Nikkei reports	06-30
Eisai and Biogen launch Alzheimer's drug Leqembi in China	06-28
Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China	06-28
Biogen executive plays down looming competition for its Alzheimer's drug	06-12
Japan's Nikkei gains on chip shares boost; Fed policy in focus	06-11
Japan's Nikkei rises on US stocks, heavyweight chip shares	06-11
FDA advisory panel votes in favor of data for Lilly Alzheimer's drug	06-10
US FDA advisers to review Eli Lilly Alzheimer's drug	06-10
Eisai Announces FDA Accepts Filing of Leqembi (Lecanemab-Irmb) sBLA for IV Maintenance Dosing for Treatment of Early Alzheimer's Disease	06-10
US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug	06-06
Eisai Starts Share Purchases Under 30 Billion Yen Buyback	06-04
BioArctic, Eisai's Azlheimer’s Disease Drug Wins Regulatory Nod in South Korea	05-24
Eisai's Attributable Profit Falls 23.5% in Fiscal 2024	05-16
BioArctic, Eisai Launch Rolling US FDA Application for Leqembi's Maintenance Dosing	05-15
Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA	05-15
Eisai Co., Ltd. announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.	05-15
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status	05-15
Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA	05-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Eisai Co., Ltd. OTC Markets

Equities

ESALY

US2825793092

Other languages

Filters